SCHEMBL321552

SCHEMBL321552

O=C(O)CN1CCCN(CC(=O)O)CC1

nearest known ligand 0.83

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.56
GAA P10253 1/20 0.46
ALDH1A1 P00352 4/20 0.43
SLC6A9 P48067 1/20 0.43
CYP1A2 P05177 1/20 0.43
MAPK1 P28482 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
SIGMAR1 Q99720 2/20 0.39
S1PR1 P21453 1/20 0.38
HTT P42858 1/20 0.38
ITGB3 P05106 1/20 0.37
ITGA2B P08514 1/20 0.37
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL893723 1.00 HSD17B10 (0.56) HSD17B10GAAALDH1A1SLC6A9CYP1A2
SCHEMBL3504659 1.00 HSD17B10 (0.56) HSD17B10GAAALDH1A1SLC6A9CYP1A2
SCHEMBL1065178 1.00 HSD17B10 (0.56) HSD17B10GAAALDH1A1SLC6A9CYP1A2
SCHEMBL21454626 1.00 HSD17B10 (0.56) HSD17B10GAAALDH1A1SLC6A9CYP1A2
SCHEMBL454245 1.00 HSD17B10 (0.56) HSD17B10GAAALDH1A1SLC6A9CYP1A2
SCHEMBL336249 1.00 HSD17B10 (0.56) HSD17B10GAAALDH1A1SLC6A9CYP1A2
SCHEMBL17512849 1.00 HSD17B10 (0.56) HSD17B10GAAALDH1A1SLC6A9CYP1A2
SCHEMBL21320722 0.97 HSD17B10 (0.54) HSD17B10GAAALDH1A1SLC6A9CYP1A2
SCHEMBL1661688 0.97
SCHEMBL661575 0.97 HSD17B10 (0.58) HSD17B10GAAALDH1A1SLC6A9CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3003395-B1 FLUORESCENT SOLID LIPID NANOPARTICLES COMPOSITION AND PREPARATION THEREOF BRACCO IMAGING SPA (IT) 2019-07-17 EP disclosed
US-8921319-B2 Serine protease inhibitors THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) 2014-12-30 US disclosed
EP-2590945-B1 SERINE PROTEASE INHIBITORS MEDICINES CO LEIPZIG GMBH (DE) 2014-04-30 EP disclosed
US-20130267467-A1 SERINE PROTEASE INHIBITORS THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) 2013-10-10 US disclosed
EP-2590945-A2 SERINE PROTEASE INHIBITORS The Medicines Company (Leipzig) GmbH (DE) 2013-05-15 EP disclosed
WO-2012004678-A2 SERINE PROTEASE INHIBITORS THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130267467-A1 SERINE PROTEASE INHIBITORS SERPINE1, KLKB1, SERPINC1 HSD17B10 910/4885GAA 2947/4885ALDH1A1 1922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.